Analytic performance studies and clinical reproducibility of a real-time PCRassay for the detection of epidermal growth factor receptor gene mutations informalin-fixed paraffin-embedded tissue specimens of non-small cell lungcancer-Reference-Cited by-同舟云学术

Analytic performance studies and clinical reproducibility of a real-time PCRassay for the detection of epidermal growth factor receptor gene mutations informalin-fixed paraffin-embedded tissue specimens of non-small cell lungcancer

Published:2013-04-27 Issue:1 Volume:13 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

O’Donnell Patrick,Ferguson Jane,Shyu Johnny,Current Robert,Rehage Taraneh,Tsai Julie,Christensen Mari,Tran Ha Bich,Chien Sean Shih-Chang,Shieh Felice,Wei Wen,Lawrence H Jeffrey,Wu Lin,Schilling Robert,Bloom Kenneth,Maltzman Warren,Anderson Steven,Soviero Stephen

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/1471-2407-13-210.pdf

Reference23 articles.

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. Cancer J Clin. 2011, 61 (2): 69-90. 10.3322/caac.20107.

2. Hirsch FR, Varella-Garcia M, Bunn PA, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T: Molecular predictors of outcome with gefitinib in a phase IIIplacebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006, 24 (31): 5034-5042. 10.1200/JCO.2006.06.3958.

3. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N: Biomarker analyses and final overall survival results from a phase III,randomized, open-label, first-line study of gefitinib versuscarboplatin/paclitaxel in clinically selected patients with advancednon-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011, 29 (21): 2866-2874. 10.1200/JCO.2010.33.4235.

4. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM: Erlotinib versus standard chemotherapy as first-line treatment for Europeanpatients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012, 13 (3): 239-246. 10.1016/S1470-2045(11)70393-X.

5. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S: Erlotinib versus chemotherapy as first-line treatment for patients withadvanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011, 12 (8): 735-742. 10.1016/S1470-2045(11)70184-X.

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer;International Journal of Molecular Sciences;2024-07-19

2. The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation;Frontiers in Oncology;2024-06-11

3. Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer;International Journal of Molecular Sciences;2024-05-29

4. Performance of the cobas EZH2 mutation test on clinical samples from non-Hodgkin lymphoma patients;PLOS ONE;2023-12-14

5. Analytical Performance and Concordance with Next-Generation Sequencing of a Rapid, Multiplexed dPCR Panel for the Detection of DNA and RNA Biomarkers in Non-Small-Cell Lung Cancer;Diagnostics;2023-10-25